Amoxycillin

Brogden, Rex N.; Speight, T. M.; Avery, G. S.

doi:10.2165/00003495-197407050-00003

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies have shown that disodium cromoglycate (DSCG) is of value in the treatment of bronchial asthma (Brogden, Speight & Avery, 1974). It is generally agreed that the patients most likely to respond are young atopic individuals whose symptoms may or may not be accentuated by exposure to specific allergens.…”

Section: Introductionmentioning

confidence: 99%

The orally administered anti‐allergic agent, sodium nivimedone (BRL 10833); efficacy in bronchial asthma and effects on IgE, complement and eosinophils.

Lumb¹,

McHardy²,

Kay³

1979

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Sodium nivimedone (BRL 10833) which acts similarly to disodium cromoglycate (DSCG), given at an oral dose of 200 mg thrice daily, was compared, after a preliminary standardization week, with placebo in a 6-week double-blind cross-over trial. Twenty-four non-smoking, atopic, asthmatic outpatients aged between 16 and 32 years, who were not taking corticosteroids took part. Subjects recorded symptoms and bronchodilator use each day and measured peak expiratory flow rate (PEFR) thrice daily. 2 Data was analysed separately for the twelve subjects who received placebo followed by sodium nivimedone (Group I) and those who took the treatments in the reverse order (Group II). 3 In Group I subjects, with sodium nivimedone, bronchodilator use decreased, symptom scores improved and there was a significant improvement in overall PEFR as well as the separated morning and evening values. When symptom scores were expressed as a percentage of the placebo disability index, wheezing, chest tightness, cough and asthma on activity showed significant improvement. 4 Subjects in Group II showed no improvement in any of these variables when drug was compared to placebo. 5Sodium nivimedone did not appear to have any effect on circulating eosinophil levels, and concentrations of serum IgE, C3 and C4. 6 There was no clinical or laboratory evidence that sodium nivimedone had any untoward effect in the doses given. 7 Sodium nivimedone appeared to be of benefit in the subjects studied. The importance of appreciating the order of treatments and the value of frequent serial objective and subjective measures of disability backed up by appropriate data processing is stressed.

show abstract

Section: Introductionmentioning

confidence: 99%

The orally administered anti‐allergic agent, sodium nivimedone (BRL 10833); efficacy in bronchial asthma and effects on IgE, complement and eosinophils.

Lumb¹,

McHardy²,

Kay³

1979

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

β‐Lactam Antibiotics

Testero

Fisher

Mobashery

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

The β‐lactam classes of antibacterials are preeminent in the treatment of bacterial infection due to their unparalleled clinical efficacy and clinical safety. Following the discovery of the penicillins, successive β‐lactam drug discovery has added the cephalosporin, penem cephamycin, clavulanate, monobactam, nocardicin, and carbapenem subclasses. The driving force behind much of this era of discovery is the staggering ability of pathogenic bacteria to adapt previous generations of the β‐lactam by the acquisition and expression of resistance mechanisms. Although many factors contribute to β‐lactam resistance, alterations to the molecular targets of the β‐lactams (the penicillin binding proteins) and the use of enzymes (the β‐lactamases) capable of the hydrolytic deactivation of the β‐lactams are paramount. This review traces the historical development of β‐lactam drug discovery, with emphasis on the most recent progress in the medicinal chemistry, biochemistry, and microbiology of the β‐lactams leading to the discovery of new generation β‐lactam antibacterials effective against the Gram‐negative and ‐positive bacterial pathogens of current medical concern.

show abstract

Amoxycillin

Cited by 2 publications

References 17 publications

The orally administered anti‐allergic agent, sodium nivimedone (BRL 10833); efficacy in bronchial asthma and effects on IgE, complement and eosinophils.

The orally administered anti‐allergic agent, sodium nivimedone (BRL 10833); efficacy in bronchial asthma and effects on IgE, complement and eosinophils.

β‐Lactam Antibiotics

Contact Info

Product

Resources

About